Table 1.
Commonly enriched canonical pathways among the representative shared subnetworks
| Pathway description | No. of significant pathways |
Tissue comparison | Diabetes comparison | ||
|---|---|---|---|---|---|
| Glom: STZ vs db/db |
SCN: STZ vs db/db |
STZ: SCN vs Glom |
db/db SCN vs Glom |
||
| AKT(PKB)-Bad signalling (EPO signalling pathway (JAK2 STAT1 STAT3 STAT5)) | 4 | 0.010 | <0.001 | 0.020 | <0.001 |
| AKT(PKB)-Bad signalling (IL-7 signalling (JAK1 JAK3 STAT5)) | 4 | 0.032 | <0.001 | 0.020 | <0.001 |
| Angiopoietin receptor Tie2-mediated signalling | 4 | <0.001 | <0.001 | 0.004 | <0.001 |
| Cytokine receptor degradation signalling (JAK STAT Pathway and Regulation) | 4 | 0.005 | <0.001 | 0.003 | 0.002 |
| Gene expression (VEGF signalling pathway) | 4 | 0.013 | <0.001 | 0.040 | <0.001 |
| IL-6 signalling pathway (JAK1 JAK2 STAT3) | 4 | 0.013 | <0.001 | 0.025 | 0.032 |
| IL6-mediated signalling events | 4 | <0.001 | <0.001 | 0.010 | 0.006 |
| Reelin signalling pathway | 4 | 0.004 | 0.001 | <0.001 | <0.001 |
| SHP2 signalling | 4 | 0.013 | <0.001 | 0.003 | <0.001 |
| TGFBR | 4 | 0.025 | 0.004 | 0.001 | <0.001 |
| VEGFR3 signalling in lymphatic endothelium | 4 | <0.001 | <0.001 | 0.020 | 0.001 |
| Bioactive peptide-induced signalling pathway | 3 | 0.032 | 0.013 | <0.001 | |
| Co-regulation of androgen receptor activity | 3 | 0.032 | 0.050 | 0.005 | |
| Cyclins and cell cycle regulation | 3 | <0.001 | 0.002 | 0.005 | |
| Ephrin B reverse signalling | 3 | 0.032 | 0.006 | 0.010 | |
| HIF-1-α transcription factor network | 3 | 0.001 | 0.013 | 0.002 | |
| IGF-1 pathway | 3 | 0.001 | 0.006 | 0.016 | |
| IGF-1 signalling pathway | 3 | <0.001 | 0.050 | 0.016 | |
| Inhibition of cellular proliferation by Gleevec | 3 | <0.001 | 0.013 | 0.025 | |
| Integrins in angiogenesis | 3 | 0.013 | 0.016 | 0.003 | |
| JAK_STAT_MolecularVariation_1 | 3 | 0.008 | 0.020 | 0.020 | |
| JAK_STAT_MolecularVariation_2 | 3 | <0.001 | <0.001 | 0.016 | |
| KitReceptor | 3 | <0.001 | 0.032 | 0.016 | |
| Regulation of bad phosphorylation | 3 | 0.004 | <0.001 | 0.025 | |
| Signalling events mediated by TCPTP | 3 | 0.003 | 0.016 | 0.025 | |
| Signalling events mediated by VEGFR1 and VEGFR2 | 3 | 0.003 | 0.040 | 0.006 | |
| Syndecan-2-mediated signalling events | 3 | 0.013 | 0.005 | 0.020 | |
| Syndecan-4-mediated signalling events | 3 | <0.001 | 0.002 | 0.005 | |
| IGF-1 receptor and longevity | 3 | <0.001 | 0.025 | 0.001 | |
| Validated targets of C-MYC transcriptional repression | 3 | <0.001 | 0.005 | 0.005 | |
The values reported in this table represent the false discovery rate (FDR) for each comparison. No. of significant pathways: the number of comparisons in which the corresponding signalling pathway was significantly over-represented. C-MYC, c-myc avian myelocytomatosis viral oncogene homolog; EPO, erythropoietin; HIF-1-α, hypoxia-inducible factor 1-alpha; SPH2, SH2 domain-containing tyrosine phosphatase; TCPTP, T-cell protein tyrosine phosphatase; TGFBR, transforming growth factor beta receptor; VEGF, vascular endothelial growth factor